LSZ

Discovery

LSZ was synthesized in 2002 by David Nichols and colleagues at Purdue University as part of a structure-activity study exploring how LSD's amide group binds to the 5-HT₂A receptor.^[2] Three diastereomers were prepared; only the (2S,4S) isomer exhibited binding affinity and behavioral potency matching LSD, demonstrating that this specific geometry approximates LSD's optimal receptor binding orientation.^[2]

Scientific significance

LSZ's value was primarily as a research tool — its rigid azetidine ring locked LSD's flexible amide group into a defined shape, allowing researchers to determine which spatial orientation activates the receptor. The finding that only one of three possible geometries produced LSD-like effects^[2] contributed to understanding how lysergamides interact with 5-HT₂A at the molecular level. The compound attracted no clinical interest and was not investigated further by the original research group.

Novel psychoactive substance market

LSZ appeared on European designer drug markets in December 2013, distributed as powder and on blotter paper.^[1] Analytical testing of commercial blotters labeled at 150 µg found actual content of approximately 112–131 µg.^[1] The United Kingdom classified LSZ as a Class A substance in January 2015, with Denmark, Switzerland, and Sweden following within a year.^[5]

Structure

LSZ belongs to the lysergamide family — ergoline derivatives built on a tetracyclic indole ring system with an amide group at the C-9 position. Where LSD carries an N,N-diethylamide at this position, LSZ replaces it with a (2S,4S)-2,4-dimethylazetidine ring — a four-membered nitrogen cycle that locks the amide into a fixed geometric orientation.^[2]

This conformational restriction was the design rationale: by eliminating rotational freedom in the amide group, Nichols and colleagues could determine which spatial orientation is required for potent serotonin receptor binding.^[2]

Stereochemistry and structure-activity relationships

Three diastereomers were synthesized: (2'S,4'S)-(+), (2'R,4'R)-(−), and cis.^[2] Only the (S,S) isomer — LSZ — showed potent receptor binding and LSD-like behavioral activity; the (R,R) and cis forms were markedly less active in all assays.^[2] This stereoselective result confirmed that the (S,S) configuration positions the azetidine methyl groups in the same spatial orientation that LSD's diethylamide adopts when bound to its receptor.^[2]

N-Ethyl-N-cyclopropyl lysergamide (ECPLA) is a constitutional isomer of LSZ sharing the same molecular formula. The two can be distinguished analytically — under mass spectrometry conditions, LSZ produces characteristic fragment ions absent in ECPLA.^[7]

Physical form

LSZ is distributed as both the free base (powder) and the tartrate salt (blotter).^[1] No melting point, solubility, or stability data have been published for either form.

Mechanism of action

LSZ produces its psychedelic effects primarily through activation of the serotonin 5-HT₂A receptor.^[2][1] Three converging lines of evidence support this: the mouse head-twitch response induced by LSZ is fully blocked by the selective 5-HT₂A antagonist M100907;^[1] potency across LSZ's three diastereomers correlates directly with their 5-HT₂A binding affinity;^[2] and the 5-HT₂A antagonist ketanserin blocks nearly all acute subjective effects of LSD in humans.^[8]

Like other lysergamides, LSZ likely engages a broad range of receptors beyond its primary target. LSD binds dopamine D1 and D2 receptors with substantial affinity,^[9] and a comprehensive screen of classical psychedelics confirmed potent lysergamide actions across serotonin, dopamine, and adrenergic receptor families.^[10]

LSD also activates dopamine D2 receptors in a temporally delayed second phase, potentially contributing to late-stage effects distinct from the initial serotonergic experience.^[11] Whether LSZ shares this biphasic profile is unknown.

Pharmacokinetics

No human pharmacokinetic data exist for LSZ. Class-level reference values from controlled LSD studies suggest an oral onset of 1–2 hours, subjective duration of approximately 7–11 hours depending on dose, and an half-life of roughly 3–5 hours at full doses.^{[12][13][14][15]}

LSZ-specific metabolism data come from human liver fraction studies: the primary pathways are N-dealkylation and hydroxylation, mediated principally by CYP1A2 and CYP3A4 enzymes.^[16] The parent compound was undetectable in rat urine at expected recreational doses, meaning specialized testing is required for forensic identification.^[16]

Individual variation in these metabolic enzymes — influenced by genetics, smoking, and co-administered drugs — may substantially alter LSZ's effective duration and intensity.

Where it acts

No neuroimaging or electrophysiological studies have been conducted with LSZ. By mechanism, its neural effects are inferred from LSD and other serotonin 2A receptor agonists.

Activation of serotonin receptors on neurons in the prefrontal cortex disrupts the brain's default mode network and loosens thalamocortical gating — the filtering system that normally constrains which sensory information reaches conscious awareness. The result is increased connectivity between brain regions that do not ordinarily communicate, experienced as the fluid, boundary-dissolving quality characteristic of the psychedelic state.

Why it matters

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A activation weakens the brain's reliance on prior expectations, allowing raw sensory data to reshape entrenched patterns of thought and perception. This framework accounts for the characteristic dissolution of habitual thought patterns and ego boundaries observed with lysergamides.

Separately, LSD binds the TrkB neurotrophin receptor with approximately 1,000-fold higher affinity than classical antidepressants, promoting structural brain plasticity through a mechanism independent of 5-HT₂A activation.^[17] Whether LSZ engages TrkB with comparable affinity is unknown.

Toxicity

The closest class reference is a series of eight massive LSD overdoses in which patients ingested pure LSD powder at doses vastly exceeding recreational use; all eight survived with supportive care.^[18] Only two deaths in the historical literature have been attributed to direct LSD toxicity — the vast majority of LSD-associated fatalities involve behavioral consequences during intoxication rather than organ failure.

LSZ has estimated binding activity at serotonin₂B receptors^[5] — a receptor linked to heart valve damage when chronically activated by ergot-derived compounds.^[20] At typical psychedelic use frequencies this risk is theoretical; with heavy chronic use, cardiac monitoring would be warranted.

Psychological risks

Anxiety, panic, paranoia, and psychosis are recognized risks of classical psychedelics.^[3] Individuals with personal or family history of psychotic disorders are at elevated risk.

At doses equivalent to LSD 200 µg — roughly the upper end of common LSZ doses — anxiety and ego dissolution increase significantly beyond levels seen at lower doses.^[15][19] Given LSZ's equipotency with LSD, similar dose-dependent escalation of distress is expected.

Hallucinogen persisting perception disorder (HPPD) is a rare but documented adverse effect.^[4] Type 1 consists of brief episodic flashbacks; Type 2 involves chronic persistent visual phenomena lasting months to years. No LSZ-specific HPPD cases have been published.

Tolerance and dependence

Tolerance develops rapidly after a single dose through downregulation in the frontal cortex,^[21][22] with a half-life of approximately 3 days and full reset within about 7 days. Full cross-tolerance exists with other serotonergic psychedelics (LSD, psilocybin, mescaline, DMT).^[21]

Classical psychedelics are not considered habit-forming and do not produce physical withdrawal.^[3][23] Dependence liability is negligible.

LSZ is not controlled under the United Nations Single Convention on Narcotic Drugs (1961) or the Convention on Psychotropic Substances (1971).^[32] National scheduling varies widely: several European jurisdictions have specifically listed LSZ, while others rely on structural analog or blanket provisions. In the United States, LSZ is not a scheduled substance under federal law, but the Federal Analogue Act may apply when sold for human consumption as an analog of Schedule I LSD.

Analog and blanket provisions

LSZ's structural relationship to LSD is unambiguous — it retains the full ergoline tetracyclic core and differs only in the amide substituent. In jurisdictions with analog or "substantially similar" provisions (US Federal Analogue Act, Canadian CDSA analogue clause), LSZ may be prosecuted as an LSD analogue when intended for human consumption, even without explicit scheduling.

Germany's NpSG takes a broader approach, controlling new psychoactive substances by structural class rather than individual listing.^[5]